S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
GE   8.79 (-1.90%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
ACB   3.69 (+0.27%)
PRI   125.69 (+1.75%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
GILD   65.22 (+0.48%)
DIS   130.26 (-0.48%)
Log in

SpringWorks Therapeutics Stock Price, News & Analysis (NASDAQ:SWTX)

$20.60
+1.33 (+6.90 %)
(As of 10/21/2019 04:00 PM ET)
Today's Range
$19.14
Now: $20.60
$20.81
50-Day Range N/A
52-Week Range
$17.66
Now: $20.60
$28.62
Volume110,200 shs
Average Volume200,452 shs
Market Capitalization$862.77 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its advanced product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; and Nirogacestat + belantamab mafodotin, which is in Phase 1b clinical trials for the treatment of relapsed or refractory multiple myeloma. In addition, it is developing Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trials in patients with advanced or refractory solid tumors; and BGB-3245, an investigational oral selective small molecule inhibitor of specific BRAF driver mutations and genetic fusions, which is in preclinical studies in a range of tumor models with BRAF mutations or fusions. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline plc to develop combination approaches with nirogacestat and mirdametinib, as well as other standalone medicines. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SWTX
CUSIPN/A
CIKN/A
Phone203-883-9490

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees52
Market Cap$862.77 million
Next Earnings DateN/A
OptionableNot Optionable

Receive SWTX News and Ratings via Email

Sign-up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter.


SpringWorks Therapeutics (NASDAQ:SWTX) Frequently Asked Questions

What is SpringWorks Therapeutics' stock symbol?

SpringWorks Therapeutics trades on the NASDAQ under the ticker symbol "SWTX."

What price target have analysts set for SWTX?

4 brokers have issued 12-month target prices for SpringWorks Therapeutics' stock. Their predictions range from $32.00 to $37.00. On average, they anticipate SpringWorks Therapeutics' stock price to reach $34.00 in the next year. This suggests a possible upside of 65.0% from the stock's current price. View Analyst Price Targets for SpringWorks Therapeutics.

What is the consensus analysts' recommendation for SpringWorks Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SpringWorks Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SpringWorks Therapeutics.

Has SpringWorks Therapeutics been receiving favorable news coverage?

News articles about SWTX stock have trended somewhat positive on Monday, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. SpringWorks Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for SpringWorks Therapeutics.

Who are some of SpringWorks Therapeutics' key competitors?

Who are SpringWorks Therapeutics' key executives?

SpringWorks Therapeutics' management team includes the folowing people:
  • Mr. Saqib Islam, CEO & Director (Age 49)
  • Dr. Jens Renstrup M.B.A., M.D., Chief Medical Officer (Age 54)
  • Dr. Badreddin Edris Ph.D., Chief Bus. Officer (Age 32)
  • Dr. Stephen P. Squinto, Acting Head of R&D and Director (Age 63)
  • Mr. Francis I. Perier Jr., Chief Financial Officer (Age 59)

When did SpringWorks Therapeutics IPO?

(SWTX) raised $126 million in an initial public offering on Friday, September 13th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. ​J.P. Morgan, Goldman Sachs and Cowen​ ​ served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

When does the company's quiet period expire?

SpringWorks Therapeutics' quiet period expires on Wednesday, October 23rd. SpringWorks Therapeutics had issued 9,000,000 shares in its public offering on September 13th. The total size of the offering was $162,000,000 based on an initial share price of $18.00. During the company's quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of SpringWorks Therapeutics?

Shares of SWTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is SpringWorks Therapeutics' stock price today?

One share of SWTX stock can currently be purchased for approximately $20.60.

How big of a company is SpringWorks Therapeutics?

SpringWorks Therapeutics has a market capitalization of $862.77 million. SpringWorks Therapeutics employs 52 workers across the globe.View Additional Information About SpringWorks Therapeutics.

What is SpringWorks Therapeutics' official website?

The official website for SpringWorks Therapeutics is http://www.springworkstx.com/.

How can I contact SpringWorks Therapeutics?

SpringWorks Therapeutics' mailing address is 100 WASHINGTON BOULEVARD, STAMFORD CT, 06902. The company can be reached via phone at 203-883-9490 or via email at [email protected]


MarketBeat Community Rating for SpringWorks Therapeutics (NASDAQ SWTX)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  6 (Vote Outperform)
Underperform Votes:  2 (Vote Underperform)
Total Votes:  8
MarketBeat's community ratings are surveys of what our community members think about SpringWorks Therapeutics and other stocks. Vote "Outperform" if you believe SWTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SWTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel